Aroa Biosurgery (ASX:ARX) Debt-to-EBITDA : -1.78 (As of Sep. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Aroa Biosurgery Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Aroa Biosurgery's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was A$0.78 Mil. Aroa Biosurgery's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was A$5.50 Mil. Aroa Biosurgery's annualized EBITDA for the quarter that ended in Sep. 2023 was A$-3.52 Mil. Aroa Biosurgery's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 was -1.78.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Aroa Biosurgery's Debt-to-EBITDA or its related term are showing as below:

ASX:ARX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.17 Med: -1.12 Max: 2.05
Current: -2.17

During the past 4 years, the highest Debt-to-EBITDA Ratio of Aroa Biosurgery was 2.05. The lowest was -2.17. And the median was -1.12.

ASX:ARX's Debt-to-EBITDA is ranked worse than
100% of 430 companies
in the Medical Devices & Instruments industry
Industry Median: 1.225 vs ASX:ARX: -2.17

Aroa Biosurgery Debt-to-EBITDA Historical Data

The historical data trend for Aroa Biosurgery's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aroa Biosurgery Debt-to-EBITDA Chart

Aroa Biosurgery Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Debt-to-EBITDA

N/A

-1.12

-1.34

2.05

Aroa Biosurgery Semi-Annual Data
	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Debt-to-EBITDA	Get a 7-Day Free Trial			-1.17	-1.74	0.56	-2.96	-1.78

Competitive Comparison of Aroa Biosurgery's Debt-to-EBITDA

For the Medical Devices subindustry, Aroa Biosurgery's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aroa Biosurgery's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Aroa Biosurgery's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Aroa Biosurgery's Debt-to-EBITDA falls into.

Aroa Biosurgery Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Aroa Biosurgery's Debt-to-EBITDA for the fiscal year that ended in Mar. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.523	+	6.129)	/	3.241
	=	2.05

Aroa Biosurgery's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.775	+	5.498)	/	-3.522
	=	-1.78

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Sep. 2023) EBITDA data.

Aroa Biosurgery (ASX:ARX) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Aroa Biosurgery Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Aroa Biosurgery's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Aroa Biosurgery (ASX:ARX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Aroa Biosurgery Ltd (ASX:ARX) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

64 Richard Pearse Drive, Mangere, Airport Oaks, Auckland, NZL, 2022

Website

https://www.aroabio.com

Aroa Biosurgery Ltd is a soft tissue regeneration company which develops, manufactures and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The Company is in the business of developing, manufacturing and selling soft tissue repair products. The company's principal market is the United States where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery and trauma/limb salvage/tumor surgery.

Aroa Biosurgery (ASX:ARX) Headlines

No Headlines